Personalised mRNA vaccine plus Keytruda halts melanoma relapse in trial
TL;DR Summary
A phase 3 trial of a personalised mRNA vaccine (Intismeran) given with Keytruda after melanoma surgery extended disease-free time in over 1,000 high-risk patients. While the interim results are promising, they have not yet been peer-reviewed and regulatory approval is still required before NHS rollout.
- Vaccine breakthrough stops cancer returning in trial BBC
- Moderna’s Shift to Cancer Company Lifts Stock Up 177% The New York Times
- New mRNA vaccine could reduce the recurrence and spread of skin cancer NPR
- Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar CNBC
- Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today? Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
7
Time Saved
4 min
vs 5 min read
Condensed
94%
802 → 45 words
Want the full story? Read the original article
Read on BBC